Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

INTRODUCTION: KEYNOTE-240 investigated the efficacy and safety of pembrolizumab plus best supportive care (BSC) in sorafenib-treated patients with advanced hepatocellular carcinoma (HCC). Results for the subgroup of patients from Asia are described. METHODS: Adults with advanced HCC previously treat...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Liver Cancer
Main Authors: Kudo, Masatoshi, Lim, Ho Yeong, Cheng, Ann-Lii, Chao, Yee, Yau, Thomas, Ogasawara, Sadahisa, Kurosaki, Masayuki, Morimoto, Naoki, Ohkawa, Kazuyoshi, Yamashita, Tatsuya, Lee, Kyung-Hun, Chen, Erluo, Siegel, Abby B., Ryoo, Baek-Yeol
Format: Artigo
Sprog:Inglês
Udgivet: S. Karger AG 2021
Fag:
Original Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8237794/
https://ncbi.nlm.nih.gov/pubmed/34239813
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000515553
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker